A Healthy Volunteer Pharmacokinetics (PK)/Pharmacodynamics (PD), Safety and Tolerability Study of Andexanet in Healthy Japanese and Caucasian Subjects
NCT ID: NCT03310021
Last Updated: 2023-02-24
Study Results
Results available
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Clinical Phase
PHASE2
Total Enrollment
108 participants
Study Classification
INTERVENTIONAL
Study Start Date
2017-08-28
Study Completion Date
2019-08-13
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
"This is a single-center, randomized, double-blind, and placebo-controlled trial designed to: 1) demonstrate the degree to which administered andexanet doses can reverse Factor Ten A (FXa)-inhibitor induced anticoagulation; and 2) evaluate the safety and PK/PD of andexanet in healthy Japanese subjects taking direct FXa inhibitors at therapeutic doses."
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Healthy Volunteer PK/PD, Safety and Tolerability Study of Second Generation Andexanet Alfa
NCT03083704
Bleeding
COMPLETED
PHASE1
A Healthy Volunteer PK/PD, Safety and Tolerability Study of Andexanet After Betrixaban Dosing
NCT03330457
Bleeding
TERMINATED
PHASE2
A Study in Older Subjects to Evaluate the Safety and Ability of Andexanet Alfa to Reverse the Anticoagulation Effect of Apixaban
NCT02207725
Bleeding
COMPLETED
PHASE3
A Study in Older Subject to Evaluate the Safety and Ability of Andexanet Alfa to Reverse the Anticoagulation Effect of Rivaroxaban
NCT02220725
Bleeding
COMPLETED
PHASE3
A Study in Participants With Acute Major Bleeding to Evaluate the Ability of Andexanet Alfa to Reverse the Anticoagulation Effect of Direct and Indirect Oral Anticoagulants (Extension Study)
NCT02329327
Bleeding
COMPLETED
PHASE3
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Bleeding
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
Primary Study Purpose
TREATMENT
Blinding Strategy
TRIPLE
Participants
Caregivers
Investigators
Double Blind (Participant, Care Provider, Investigator, Sponsor)
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cohort 1
Apixaban + low dose andexanet
Group Type
EXPERIMENTAL
Andexanet alfa
Intervention Type
BIOLOGICAL
fXa inhibitor antidote
Apixaban
Intervention Type
DRUG
factor Xa inhibitor
Placebo
Intervention Type
DRUG
Placebo
Cohort 2
Rivaroxaban + high dose andexanet
Group Type
EXPERIMENTAL
Andexanet alfa
Intervention Type
BIOLOGICAL
fXa inhibitor antidote
Rivaroxaban
Intervention Type
DRUG
factor Xa inhibitor
Placebo
Intervention Type
DRUG
Placebo
Cohort 3
Edoxaban + high dose andexanet
Group Type
EXPERIMENTAL
Andexanet alfa
Intervention Type
BIOLOGICAL
fXa inhibitor antidote
Edoxaban
Intervention Type
DRUG
factor Xa inhibitor
Placebo
Intervention Type
DRUG
Placebo
Cohort 4
Edoxaban + high dose andexanet
Group Type
EXPERIMENTAL
Andexanet alfa
Intervention Type
BIOLOGICAL
fXa inhibitor antidote
Edoxaban
Intervention Type
DRUG
factor Xa inhibitor
Placebo
Intervention Type
DRUG
Placebo
Cohort 5
Apixaban + low dose andexanet
Group Type
EXPERIMENTAL
Andexanet alfa
Intervention Type
BIOLOGICAL
fXa inhibitor antidote
Apixaban
Intervention Type
DRUG
factor Xa inhibitor
Placebo
Intervention Type
DRUG
Placebo
Cohort 6
Apixaban + high dose andexanet
Group Type
EXPERIMENTAL
Andexanet alfa
Intervention Type
BIOLOGICAL
fXa inhibitor antidote
Apixaban
Intervention Type
DRUG
factor Xa inhibitor
Placebo
Intervention Type
DRUG
Placebo
Cohort 7
Edoxaban + low dose andexanet
Group Type
EXPERIMENTAL
Andexanet alfa
Intervention Type
BIOLOGICAL
fXa inhibitor antidote
Edoxaban
Intervention Type
DRUG
factor Xa inhibitor
Placebo
Intervention Type
DRUG
Placebo
Cohort 8
Apixaban + low dose andexanet
Group Type
EXPERIMENTAL
Andexanet alfa
Intervention Type
BIOLOGICAL
fXa inhibitor antidote
Apixaban
Intervention Type
DRUG
factor Xa inhibitor
Placebo
Intervention Type
DRUG
Placebo
Cohort 9
Rivaroxaban + low dose andexanet
Group Type
EXPERIMENTAL
Andexanet alfa
Intervention Type
BIOLOGICAL
fXa inhibitor antidote
Rivaroxaban
Intervention Type
DRUG
factor Xa inhibitor
Placebo
Intervention Type
DRUG
Placebo
Cohort 10
Edoxaban + low dose andexanet
Group Type
EXPERIMENTAL
Andexanet alfa
Intervention Type
BIOLOGICAL
fXa inhibitor antidote
Edoxaban
Intervention Type
DRUG
factor Xa inhibitor
Placebo
Intervention Type
DRUG
Placebo
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Andexanet alfa
fXa inhibitor antidote
Intervention Type
BIOLOGICAL
Apixaban
factor Xa inhibitor
Intervention Type
DRUG
Rivaroxaban
factor Xa inhibitor
Intervention Type
DRUG
Edoxaban
factor Xa inhibitor
Intervention Type
DRUG
Placebo
Placebo
Intervention Type
DRUG
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
200 mg/vial for IV injection
Eliquis
Xarelto
Savaysa, Lixiana
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Must be in reasonably good health as determined by the Investigator based on medical history, full physical examination (including blood pressure and pulse rate measurement), 12-lead ECG, and clinical laboratory tests. Subjects with well-controlled, chronic, stable conditions (e.g., controlled hypertension, non-insulin dependent diabetes, osteoarthritis, hypothyroidism) may be enrolled based on the clinical judgment of the Investigator.
2. For all cohorts except Cohort 5, subjects must be of Japanese ethnicity, defined as having four ethnic Japanese grandparents. Subjects may not have lived outside of Japan for more than 10 years. For Cohort 5, subjects must be of Caucasian race.
3. Must be between the ages of 18 and 75 years, inclusive, at the time of signing of the Inform Consent Form (ICF).
4. Agrees to have any dietary or nutritional supplements reviewed by the Investigator and potentially held during the study if advised by the Investigator. Standard multivitamin and mineral supplementation will be permitted.
5. Agrees to comply with the contraception and reproduction restrictions of the study:
* Men whose sexual partner is of childbearing potential and/or who are not monogamous must be using two acceptable methods of contraception, at least one of which must be a barrier method (e.g., spermicidal gel plus condom), for the entire duration of the study and for at least 1 month following study-drug administration; and men must refrain from attempting to father a child or donating sperm in the 1 month following the study-drug administration. Periodic abstinence (e.g., calendar, ovulation, symptothermal, postovulation methods) and withdrawal are not acceptable methods of contraception.
* Men who report surgical sterilization (e.g., bilateral vasectomy) must have had the procedure at least 6 months before study drug administration.
* Surgical sterilization procedures should be supported with clinical documentation and noted in the Relevant Medical History/Current Medical Conditions section of the case report forms (CRFs).
* Women of childbearing potential must be using two medically acceptable methods of contraception, at least one of which must be a barrier method (e.g., non-hormone containing intra-uterine device plus condom, spermicidal gel plus condom, diaphragm plus condom), from the time of Screening and for the duration of the study, through at least 1 month following study drug administration. Note: Oral and topical hormonal contraceptive use, as well as the use of hormone-containing intra-uterine devices, is not permitted due to their increased risk of thromboembolism. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post- ovulation methods) and withdrawal are not acceptable methods of contraception; OR
* Postmenopausal women must have had no regular menstrual bleeding for at least 1 year before initial dosing and either be over the age of 60 years or have an elevated plasma follicle-stimulating hormone (FSH) level (i.e., \> 40 milli-international units (mIU)/mL) at Screening;
* Women who report surgical sterilization (i.e., hysterectomy, tubal ligation, and/or bilateral oophorectomy) must have had the procedure at least 6 months before study drug administration. Surgical sterilization procedures should be supported with clinical documentation and noted in the Relevant Medical History/Current Medical Conditions section of the CRF; AND All female subjects must have a documented negative pregnancy test result at Screening and on Study Day -1.
6. Systolic blood pressure \< 160 mmHg and diastolic blood pressure \< 90 mmHg at Screening and Day -1.
7. The following laboratory values must be within the normal laboratory reference range within 45 days of Day -1: Prothrombin Time (PT), Activated Partial Thromboplastin Time (aPTT), and Activated Clotting Time (ACT); hemoglobin, hematocrit, and platelet count.
8. The following laboratory values must be equal to or below 2 times the upper limit of normal (ULN) range within 45 days of Day -1: Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) and total bilirubin.
9. The Screening serum creatinine must be below 1.5 mg/dL within 45 days of Day -1.
10. Body mass index of less than 30 kg/m2, inclusive, and body weight between 50 kg and 80 kg, inclusive. In addition, subjects must be greater than 60 kg for Cohorts 3, 4, and 10.
11. Agrees to abstain from alcohol consumption for the duration of the domicile period, and from the use of drugs of abuse for the duration of the study.
12. Able to read and give written informed consent and has signed a consent form approved by the Investigator's Institutional Review Board (IRB) or Independent Ethics Committee (IEC)."
2. For all cohorts except Cohort 5, subjects must be of Japanese ethnicity, defined as having four ethnic Japanese grandparents. Subjects may not have lived outside of Japan for more than 10 years. For Cohort 5, subjects must be of Caucasian race.
3. Must be between the ages of 18 and 75 years, inclusive, at the time of signing of the Inform Consent Form (ICF).
4. Agrees to have any dietary or nutritional supplements reviewed by the Investigator and potentially held during the study if advised by the Investigator. Standard multivitamin and mineral supplementation will be permitted.
5. Agrees to comply with the contraception and reproduction restrictions of the study:
* Men whose sexual partner is of childbearing potential and/or who are not monogamous must be using two acceptable methods of contraception, at least one of which must be a barrier method (e.g., spermicidal gel plus condom), for the entire duration of the study and for at least 1 month following study-drug administration; and men must refrain from attempting to father a child or donating sperm in the 1 month following the study-drug administration. Periodic abstinence (e.g., calendar, ovulation, symptothermal, postovulation methods) and withdrawal are not acceptable methods of contraception.
* Men who report surgical sterilization (e.g., bilateral vasectomy) must have had the procedure at least 6 months before study drug administration.
* Surgical sterilization procedures should be supported with clinical documentation and noted in the Relevant Medical History/Current Medical Conditions section of the case report forms (CRFs).
* Women of childbearing potential must be using two medically acceptable methods of contraception, at least one of which must be a barrier method (e.g., non-hormone containing intra-uterine device plus condom, spermicidal gel plus condom, diaphragm plus condom), from the time of Screening and for the duration of the study, through at least 1 month following study drug administration. Note: Oral and topical hormonal contraceptive use, as well as the use of hormone-containing intra-uterine devices, is not permitted due to their increased risk of thromboembolism. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post- ovulation methods) and withdrawal are not acceptable methods of contraception; OR
* Postmenopausal women must have had no regular menstrual bleeding for at least 1 year before initial dosing and either be over the age of 60 years or have an elevated plasma follicle-stimulating hormone (FSH) level (i.e., \> 40 milli-international units (mIU)/mL) at Screening;
* Women who report surgical sterilization (i.e., hysterectomy, tubal ligation, and/or bilateral oophorectomy) must have had the procedure at least 6 months before study drug administration. Surgical sterilization procedures should be supported with clinical documentation and noted in the Relevant Medical History/Current Medical Conditions section of the CRF; AND All female subjects must have a documented negative pregnancy test result at Screening and on Study Day -1.
6. Systolic blood pressure \< 160 mmHg and diastolic blood pressure \< 90 mmHg at Screening and Day -1.
7. The following laboratory values must be within the normal laboratory reference range within 45 days of Day -1: Prothrombin Time (PT), Activated Partial Thromboplastin Time (aPTT), and Activated Clotting Time (ACT); hemoglobin, hematocrit, and platelet count.
8. The following laboratory values must be equal to or below 2 times the upper limit of normal (ULN) range within 45 days of Day -1: Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) and total bilirubin.
9. The Screening serum creatinine must be below 1.5 mg/dL within 45 days of Day -1.
10. Body mass index of less than 30 kg/m2, inclusive, and body weight between 50 kg and 80 kg, inclusive. In addition, subjects must be greater than 60 kg for Cohorts 3, 4, and 10.
11. Agrees to abstain from alcohol consumption for the duration of the domicile period, and from the use of drugs of abuse for the duration of the study.
12. Able to read and give written informed consent and has signed a consent form approved by the Investigator's Institutional Review Board (IRB) or Independent Ethics Committee (IEC)."
Exclusion Criteria
1. Previous use of andexanet or previous participation in the current study (even if the subject received placebo).
2. History of abnormal bleeding, signs or symptoms of active bleeding, or risk factors for bleeding.
3. Has a stool specimen that was positive for occult blood within 6 months of study Screening or during the Screening Period.
4. Past or current medical history of thrombosis, any sign or symptom that suggests an increased risk of a systemic thrombotic condition or thrombotic event, or recent events that may increase risk of thrombosis.
a. For example, subjects with a known or suspected hypercoagulable state, history of Venous Thromboembolism(VTE), Deep Venous Thrombosis (DVT), stroke, myocardial infarction (MI), cancer (other than non-melanoma skin cancer), atrial fibrillation, heart failure, cardiomyopathy, phlebitis, lower extremity edema, major surgery, or trauma within 2 months of Study Day -1, airplane travel with a planned flight time for any single flight segment ≥ 6 hours during the 4 weeks prior to Study Day -1, or general immobility are excluded.
5. Absolute or relative contraindication to anticoagulation or treatment with apixaban, rivaroxaban, and/or edoxaban.
6. Prior consumption of (by any route) one or more doses of aspirin (including baby aspirin), salicylate or subsalicylate, other antiplatelet drugs (e.g., ticlopidine, clopidogrel), non-steroidal anti-inflammatory drugs, fibrinolytic, or any anticoagulant within 7 days prior to Day -1 or is anticipated to require such drugs during the study.
7. Receipt of (by any route) hormonal contraception, post- menopausal hormone replacement therapy (HRT) (including over-the-counter products), or testosterone during the 4 weeks prior to Study Day -1 or is anticipated to require such drugs during the study.
8. Family history of or risk factors for a hypercoagulable or thrombotic condition, including one of the following:
1. Factor V Leiden carrier or homozygote.
2. Protein C, S, or ATIII activity below the normal range.
9. History of adult asthma or chronic obstructive pulmonary disease or current regular or as needed use of inhaled medications.
10. Active Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), or HIV-1/2 infection.
11. Use of any drugs that are strong dual inhibitors or inducers of CYP3A4 (apixaban and rivaroxaban cohorts only) and P-gp (all cohorts) within 7 days prior to Study Day -1 or anticipated need for such drugs during the study.
12. Participation in an investigational drug study within 45 days of Day -1 or Day -1 is within 5 half-lives of the investigational compound.
13. Positive screen for drugs of abuse at Day -1 that is not explained by a prescription medication that the subject is known to be taking.
14. A medical or surgical condition that may impair drug (anticoagulant or andexanet) metabolism.
15. Allergy to any of the vehicle ingredients: Tris, arginine, sucrose, hydrochloric acid, mannitol, and polysorbate 80.
16. Allergy to soy or soy products.
17. Current breastfeeding or a positive pregnancy test at Screening or Day -1.
18. Any condition that could interfere with, or for which the treatment might interfere with, the conduct of the study or interpretation of the study results, or that would in the opinion of the Investigator increase the risk of the subject's participation in the study. This would include but is not limited to alcoholism, drug dependency or abuse, psychiatric disease, epilepsy, or any unexplained blackouts.
19. The subject is not judged by the study staff to have adequate bilateral venous access.
20. Unwillingness to adhere to the activity requirements of the study."
2. History of abnormal bleeding, signs or symptoms of active bleeding, or risk factors for bleeding.
3. Has a stool specimen that was positive for occult blood within 6 months of study Screening or during the Screening Period.
4. Past or current medical history of thrombosis, any sign or symptom that suggests an increased risk of a systemic thrombotic condition or thrombotic event, or recent events that may increase risk of thrombosis.
a. For example, subjects with a known or suspected hypercoagulable state, history of Venous Thromboembolism(VTE), Deep Venous Thrombosis (DVT), stroke, myocardial infarction (MI), cancer (other than non-melanoma skin cancer), atrial fibrillation, heart failure, cardiomyopathy, phlebitis, lower extremity edema, major surgery, or trauma within 2 months of Study Day -1, airplane travel with a planned flight time for any single flight segment ≥ 6 hours during the 4 weeks prior to Study Day -1, or general immobility are excluded.
5. Absolute or relative contraindication to anticoagulation or treatment with apixaban, rivaroxaban, and/or edoxaban.
6. Prior consumption of (by any route) one or more doses of aspirin (including baby aspirin), salicylate or subsalicylate, other antiplatelet drugs (e.g., ticlopidine, clopidogrel), non-steroidal anti-inflammatory drugs, fibrinolytic, or any anticoagulant within 7 days prior to Day -1 or is anticipated to require such drugs during the study.
7. Receipt of (by any route) hormonal contraception, post- menopausal hormone replacement therapy (HRT) (including over-the-counter products), or testosterone during the 4 weeks prior to Study Day -1 or is anticipated to require such drugs during the study.
8. Family history of or risk factors for a hypercoagulable or thrombotic condition, including one of the following:
1. Factor V Leiden carrier or homozygote.
2. Protein C, S, or ATIII activity below the normal range.
9. History of adult asthma or chronic obstructive pulmonary disease or current regular or as needed use of inhaled medications.
10. Active Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), or HIV-1/2 infection.
11. Use of any drugs that are strong dual inhibitors or inducers of CYP3A4 (apixaban and rivaroxaban cohorts only) and P-gp (all cohorts) within 7 days prior to Study Day -1 or anticipated need for such drugs during the study.
12. Participation in an investigational drug study within 45 days of Day -1 or Day -1 is within 5 half-lives of the investigational compound.
13. Positive screen for drugs of abuse at Day -1 that is not explained by a prescription medication that the subject is known to be taking.
14. A medical or surgical condition that may impair drug (anticoagulant or andexanet) metabolism.
15. Allergy to any of the vehicle ingredients: Tris, arginine, sucrose, hydrochloric acid, mannitol, and polysorbate 80.
16. Allergy to soy or soy products.
17. Current breastfeeding or a positive pregnancy test at Screening or Day -1.
18. Any condition that could interfere with, or for which the treatment might interfere with, the conduct of the study or interpretation of the study results, or that would in the opinion of the Investigator increase the risk of the subject's participation in the study. This would include but is not limited to alcoholism, drug dependency or abuse, psychiatric disease, epilepsy, or any unexplained blackouts.
19. The subject is not judged by the study staff to have adequate bilateral venous access.
20. Unwillingness to adhere to the activity requirements of the study."
Minimum Eligible Age
18 Years
Maximum Eligible Age
75 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Portola Pharmaceuticals
INDUSTRY
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
WCCT Global
Cypress, California, United States
Site Status
Countries
Review the countries where the study has at least one active or historical site.
United States
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol
Document Type: Statistical Analysis Plan: Statistical Analysis Plan Part 1
Document Type: Statistical Analysis Plan: Statistical Analysis Plan Part 2
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
16-508
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
A Study to Investigate Andexanet Dosing and the Interaction Between Andexanet and Subsequent Enoxaparin in Healthy Participants
NCT07312851
NOT_YET_RECRUITING
PHASE1
Pharmacokinetics and Point of Care Testing of Direct Oral Anticoagulants Subjects
NCT05491460
UNKNOWN
PHASE1
Phase 2 Healthy Volunteer Study to Evaluate the Ability of PRT064445 to Reverse the Effects of Several Blood Thinner Drugs on Laboratory Tests (Module 1 of 4)
NCT01758432
COMPLETED
PHASE2
Short-Term Anticoagulation Versus Antiplatelet Therapy for Preventing Device Thrombosis Following Left Atrial Appendage Closure
NCT03568890
ACTIVE_NOT_RECRUITING
PHASE4
Single Ascending Dose Study of PRT064445, a Factor Xa (fXa) Inhibitor Antidote
NCT03218241
COMPLETED
PHASE1
Phase 2 Healthy Volunteer Study to Evaluate the Ability of PRT064445 to Reverse the Effects of Several Blood Thinner Drugs on Laboratory Tests (Module 3 of 4)
NCT03551730
COMPLETED
PHASE2
Phase 2 Healthy Volunteer Study to Evaluate the Ability of PRT064445 to Reverse the Effects of Several Blood Thinner Drugs on Laboratory Tests (Module 4 of 4)
NCT03551743
COMPLETED
PHASE2
Study of Intravenous VMX-C001 in Healthy Subjects and in Combination With Selected Direct Oral Anticoagulants in Healthy Older Subjects
NCT05152420
COMPLETED
PHASE1
Pharmacokinetics, Safety and Pharmacodynamics After Multiple Oral Doses of Dabigatran Etexilate Capsule in Healthy Japanese and Caucasian Male Subjects
NCT02171468
COMPLETED
PHASE1
Relative Bioavailability and Pharmacodynamics of Dabigatran With Enoxaparin in Healthy Male and Female Volunteers
NCT02171559
COMPLETED
PHASE1
Trial of Andexanet in Patients Receiving an Oral FXa Inhibitor Who Require Urgent Surgery
NCT04233073
TERMINATED
PHASE2
Multicentric Prospective Validation of a Universal Test to Quantify Apixaban, Rivaroxaban, Danaparoid and Fondaparinux Levels
NCT04539301
RECRUITING
Evaluate the Pharmacokinetics of Warfarin When Coadministered With PEX168 in Healthy Adult Subjects
NCT02461914
COMPLETED
PHASE1
Direct Oral Anticoagulants and Venous Thromboembolism
NCT02833987
COMPLETED
Medical Need of OAC Reversal
NCT03254147
COMPLETED
A Study of JNJ-70033093 (BMS-986177) Versus Subcutaneous Enoxaparin in Participants Undergoing Elective Total Knee Replacement Surgery
NCT03891524
COMPLETED
PHASE2
Effect of Rivaroxaban on Coagulation Parameters- an ex Vivo Study
NCT00986635
COMPLETED
Compare Apixaban and Vitamin-K Antagonists in Patients With Atrial Fibrillation (AF) and End-Stage Kidney Disease (ESKD)
NCT02933697
COMPLETED
PHASE3
AStudy To Evaluate Safety And Eficacy Of Apixaban In Japanese Acute Deep Vein Thrombosis (DVT) And Pulmonary Embolism (PE) Patients
NCT01780987
COMPLETED
PHASE3
Variability of Whole Blood Clotting Time Measurements in Ex Vivo Human Blood Samples Spiked With Anticoagulants
NCT03296982
COMPLETED
Anti-Xa Levels in Critically Ill Patients Receiving Low-molecular-weight Heparin for Thromboprophylaxis in China
NCT03311984
UNKNOWN
Influence of Edoxaban on Coagulability and Thrombin Generation: An in Vitro Study Focusing on Thrombelastography
NCT02448901
UNKNOWN
Prevention of Thromboembolic Events in Total Knee Replacement Patients
NCT03393481
WITHDRAWN
PHASE2
Factor Xa Inhibitor, PRT054021, Against Enoxaparin for the Prevention of Venous Thromboembolic Events (EXPERT)
NCT00375609
COMPLETED
PHASE2
Real-time Anti-Factor Xa Measurements in Surgical Patients to Examine Enoxaparin Metabolism and Optimize Enoxaparin Dose
NCT02704052
COMPLETED
EARLY_PHASE1